Although PD-1 and TIGIT are believed to regulate distinct coinhibitory receptors, studies have indicated that the inhibition of either PD-1 or TIGIT in preclinical tumor models was less effective in the absence of CD226. The gene discussed is PDCD1; the disease is neoplasm.